Washington, DC (April 2, 2025) – UsAgainstAlzheimer’s raises deep concerns about the potential impact of recent Reduction in Force (RIF) measures on health agencies that remain critical to the fight against Alzheimer’s disease, including the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC). These agencies are key players in advancing research, approving new treatments, and implementing public health efforts that help millions of Americans affected by Alzheimer’s.  

UsAgainstAlzheimer’s Chair and Co-Founder, George Vradenburg, released the following statement regarding the proposed budget cuts: 

“We have made huge progress in the fight to end Alzheimer’s and now is not the time to cut the very agencies driving that progress. The NIH, FDA, and CDC are essential to Alzheimer’s research, prevention, and ultimately, to getting a cure. 

“Reducing their capacity will only delay the help that so many American families need and rely on. We commend the Senate for calling a hearing on these issues, and we urge them to continue the bipartisan tradition of supporting these agencies so they can find a cure to end this devastating disease.

“The Alzheimer’s community—patients, families, caregivers, and researchers—needs the support of our government now more than ever. UsAgainstAlzheimer’s is committed to working with the Administration and Congress to make sure that Alzheimer’s remains a top priority and that our public health agencies are fully equipped to meet the challenges ahead. We look forward to next week’s Congressional hearing and the opportunity to discuss specific steps to protect the nation’s commitment to preventing and ending Alzheimer’s disease.”